



RESEARCH ARTICLE

OPEN ACCESS

ALLELIC VARIANTS OF THE CYP2D6: *4, *6 AND *10 IN QUILOMBOLA COMMUNITY, MARANHÃO, BRAZIL

¹Ilka Kassandra Pereira Belfort, ²Marcelo dos Santos, ³Viviane Sousa Ferreira, ⁴Mauricio Avelar Fernandes, ⁵Allan Kardec Barros and ⁶Sally Cristina Moutinho Monteiro

¹Postgraduate Program in Biotechnology - Northeast Biotechnology Network (RENORBIO), Federal University of Maranhão, São Luís, MA, Brazil

²Multicampi School of Medical Sciences of Rio Grande do Norte, Federal University of Rio Grande do Norte, Caicó, RN, Brazil

³Postgraduate Program in Biotechnology - Northeast Biotechnology Network (RENORBIO), Federal University of Maranhão, São Luís, MA, Brazil

⁴Pharmacist, Master's degree in Adult and Children's Health

⁵Postgraduate Program in Biotechnology - Northeast Biotechnology Network (RENORBIO), Federal University of Maranhão, São Luís, MA, Brazil

⁶Adult Health Postgraduate Program, Federal University of Maranhão, São Luís, MA, Brazil

ARTICLE INFO

Article History:

Received 14th August, 2019

Received in revised form

26th September, 2019

Accepted 11th October, 2019

Published online 30th November, 2019

Key Words:

Quilombolas. CYP2D6.

Allelic Variants.

Polymorphisms.

*Corresponding author:

Ilka Kassandra Pereira Belfort

ABSTRACT

Brazil has the largest black population outside Africa and the second largest in the world, surpassed only by Nigeria. More than 40% of the Brazilian population corresponds to Afro-descendants. Genotyping of the CYP2D6 gene may serve as a predictive tool for the pharmacological effectiveness and / or toxicity of various drugs. However, due to the high cost of genetic testing, it is necessary to know the population frequencies in order to facilitate the development of clinical and laboratory strategies. Based on these, the present study aimed to verify the allelic and genotype frequencies of the *4, *6 and *10 variants of the CYP2D6 gene in a quilombola community, located in the municipality of Icatu, Maranhão, Brazil. The research was performed with 150 people, DNA samples were obtained and used for genotyping of polymorphisms, from April 2013 to June 2014. The results demonstrated the presence of genetic polymorphisms of CYP2D6 *4, *6 and *10 in the remaining population of quilombo. Detection of alleles that did not carry the studied mutations was observed in 65% of the individuals, followed by heterozygosity in 37% and homozygosity in 1%. The most prevalent polymorph was *6 with 80% of heterozygotes.

Copyright © 2019, Ilka Kassandra Pereira Belfort et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citation: Ilka Kassandra Pereira Belfort, Marcelo dos Santos, Viviane Sousa Ferreira et al., 2019. "Allelic variants of the cyp2d6: *4, *6 and *10 in quilombola community, Maranhão, Brazil", *International Journal of Development Research*, 09, (11), 31397-31399.

INTRODUCTION

The formation of the Brazilian territory had as one of its fundamental characteristics, the miscegenation of several population matrices. In this context, people from Africa played a fundamental role in the configuration of what is now Brazil (MUNANGA, 2012). Brazil has the largest black population outside Africa and the second largest in the world, surpassed only by Nigeria. More than 40% of the Brazilian population corresponds to Afro-descendants (AMABIS e MARTHO, 1996; BATISTA, 2009).

According to estimates by the Federal Government, there are, currently in the country, around 3,000 remaining quilombo areas, mainly concentrated in the states of São Paulo, Rio de Janeiro, Pará, Maranhão, Pernambuco, Mato Grosso, Mato Grosso do Sul, Bahia, Sergipe, Goiás and Amapá. Of these, more than 1,826 are certified by the Palmares Cultural Foundation (PCF), totaling around 2.2 million people. (IBGE, 2017). Regarding the State of Maranhão, there are more than 682 remaining communities of quilombos (IBGE, 2017). In Brazil, the Brazilian black population has a genetic specificity that distinguishes it from other black populations in the world,

including that of Africa itself (BRASIL, 2001). Therefore, it is known that individuals with distinct ancestries are known to vary in response to the drug, it may be attributed to a consequence of multiple factors influencing in pharmacokinetic and / or pharmacodynamic processes such as: age, gender, body mass, renal and hepatic function, concomitant therapy, nature of the disease, ethnicity, environmental and genetic factors (CLAYTON, 2006). The new gene pool contributed greatly to a high degree of variability, directly affecting most of the polymorphic genetic traits, such as the genes of the cytochrome P450 superfamily. Cytochromes P450 are hemoproteins that catalyze the metabolism of a large number of xenobiotics and endobiotics, responsible for promote the clearance of therapeutic drugs, for example (DEENEM *et al.*, 2011). With more than 100 variants and alleles, the gene encoding the CYP2D6 enzyme is the most polymorphic compared to the genes of the other enzymes in the family (ZHOU, 2009), having as characteristic a high interindividual variability in the enzymatic activity (GREGORI *et al.*, 2010; HICKS *et al.*, 2013). Genotyping of the CYP2D6 gene may serve as a predictive tool for the pharmacological effectiveness and / or toxicity of various drugs (BERNARDA *et al.*, 2005). However, due to the high cost of genetic testing, it is necessary to know the population frequencies in order to facilitate the development of clinical and laboratory strategies. Based on these, the present study aimed to verify the allelic and genotype frequencies of the *4, *6 and *10 variants of the CYP2D6 gene in a quilombola community, located in the municipality of Icatu, Maranhão, Brazil. Considering the need to add strategies for prevention and health promotion for remnants of quilombo population, this study aimed to verify the frequency of the polymorphism of CYP gene (Cytochrome) 2D6 in a quilombola community of Maranhão, since the variation of the activity of the enzyme has important therapeutic consequences, having a significant role in the development of therapeutic insufficiency or adverse events in individuals with enzymatic polymorphism (ZHOU, 2009).

mental disorders were excluded (which made it impossible to read and understand the Term of Free and Informed Consent - TCLE), as well as immunosuppressed, bedridden and children.

Genotyping: DNA was extracted from peripheral venous blood samples using QIAmp[™] DNA Mini and Blood Mini kits (Qiagen, USA) according to the manufacturer's protocols. The extracted DNA was stored at Maranhão Tumor Bank at -80 °C. The presence of CYP2D6 *4, CYP2D6 *6 and CYP2D6 *10 polymorphisms (Table 1) were investigated by PCR and restriction enzyme digestion using 100 ng of DNA as template, as previously described by Schur *et al.* (18) e Kiyotani *et al.* (19). This study was approved by the Research Ethics Committee of the Presidente Dutra University Hospital of the Federal University of Maranhão on 04/30/2012 (CEP 007/2012) and informed consent was obtained from all registered patients.

Statistical analysis: Statistical data were analyzed using SPSS Statistics 20.0. Genotypic frequencies were tested for Hardy-Weinberg Equilibrium (HWE). The chi-squared test was also used to evaluate the deviations of the allelic frequencies of the Hardy-Weinberg Equilibrium.

RESULTS AND DISCUSSION

Among the 150 individuals analyzed, the age ranged from 18 to 85 years, with a mean of 39,0 years (standard deviation \pm 19,1 years), of which 37% were men and 63% were women. According to the results obtained between the polymorphisms CYP2D6 *4, *6 and *10, in a total of 450 analyzes performed in the volunteers, was verified that 292 (65%) of the individuals did not present any of the polymorphisms studied, 153 (34%) were heterozygous for one of the polymorphisms studied and 5 (1%) of the individuals surveyed were homozygous for one of the three polymorphisms studied. Analysis of the results demonstrated the detection of CYP2D6*4 polymorphism in heterozygosity in 32,3%

Table 1. Single Nucleotide Polymorphisms (SNP) primer sequences

Polymorphism	Primers	°C	Enzyme
CYP2D6*4 rs3892097	F: 5' GCCTTCGCCAACCCTCCG 3' R: 5' AAATCCTGCTCTTCCGAGGC 3'	60	BstNI
CYP2D6*6 rs5030655	1: 5' TCCAGCTGGAATCCGGTGTGCG 3' 2: 5' GGAGCTCGCCCTGCAGAGACTCCT 3' 11: 5' TCCTCGGTCACCCA 3' Tmut: 5' GTCGCTGGAGCAGG 3'	63 / 53 (10x / 30x)	—
CYP2D6*10 rs1065852	F: 5' CCATTGGTAGTGAGGCAGGTAT 3' R: 5' CACCATCCATGTTTGTCTTCTGGT 3'	58	HpHI

MATERIAL AND METHODS

Study area: The research was carried out in the quilombo of Boca da Mata, this one has 10 hectares and approximately 60 residences (PREFEITURA MUNICIPAL ICATU, 2017). The territory is located in the North Coast Zone of the Eastern Meso-region and in the Lower Maranhense Oriental Microregion. Its population is estimated at 26 thousand inhabitants (IBGE, 2013).

Sampling: In this study, 150 DNA samples were obtained and used for genotyping of polymorphisms during the period from April 2013 to June 2014. Inclusion criteria were individuals belonging to the remaining quilombo community of Boca da Mata, older than 18 years. Pregnant women and those with

individuals and 1% homozygous, resulting in a frequency, of this allele, of 24%. A frequency of 12% for homozygous for the CYP2D6*10 allele was found. It was verified that 80% individuals of the study population presented the polymorphic *6 in heterozygosity, making this the most frequent polymorphism in the sample. In relation to the genotype frequencies of the CYP2D6 polymorphism, *4 were 21.9% as AG and 3.0% as GG. The allele frequency of the -392A allele was 86.1% and the -392G allele was 13.9%. Genotypic frequencies were in line with the Hardy-Weinberg Equilibrium (HWE) ($p > 0.05$). With the exception of CYP2D6*4, all polymorphisms analyzed were in HWE in the Brazilian population. Homozygous variants of CYP2D6 *10 were not found in the population, with the -238AA genotype found only once (0.4%) and the -308GA genotype.

The study showed that the population is in equilibrium, for variants *4 and *10, that is, there is no statistic difference between observed and expected frequencies. However, for the variant *6 ($X^2 = 28,17$) the population is not in equilibrium, because the results show a difference between observed and expected frequencies. Evidencing that this population will probably come into equilibrium after several generations. The study of this polymorphism is of great importance for the metabolism and effects of many drugs, besides being of interest to Brazil due to the vast miscegenation of the population. It is important to note that polymorphisms in CYP2D6, as well as most polymorphisms, exhibit different frequencies according to ethnicity. Therefore, different populations may express the same polymorphisms or not, or even if they express patterns of similar polymorphisms, they may be distributed at different frequencies between these populations (SISTONEN, 2007; HICKS, *et al.*, 2013).

Conclusion

The results demonstrated the presence of genetic polymorphisms of CYP2D6 *4, *6 and *10 in the population of remaining of quilombos. Detection of alleles that did not carry the mutations studied was observed in 65% of the individuals, followed by heterozygosis in 37% and homozygous in 1% of the individuals surveyed. The most prevalent polymorph was 6 with 80% of heterozygotes.

REFERÊNCIAS

INSTITUTO BRASILEIRO DE GEOGRAFIA E ESTATÍSTICA. (IBGE). Population. Available at: <http://www.ibge.gov.br/home/mapa_site/mapa_site.php#populacao> Accessed on January 2, 2017.
AMABIS, J.M; MARTHO, G.R. Biology of Populations. São Paulo, Ed Moderna, 1996.

BATISTA, Luís Eduardo. Health in the Quilombos. São Paulo: Health Institute, SESSP. 2009.
BRASILEIRO INSTITUTE OF GEOGRAPHY AND STATISTICS (IBGE). Population. Available at: <http://www.ibge.gov.br/home/mapa_site/mapa_site.php#populacao> Accessed on January 2, 2013.
BRAZIL. Manual of the most important diseases, for ethnic reasons, in the Afrodescendant Brazilian population, Brasilia, 2001.
CLAYTON TA, et al. Pharmaco-metabonomic phenotyping and personalized drug treatment. *Nature*, v. 20, n. 440. 2006.
GREGORI M, et al. How and Why to Screen for CYP2D6 Interindividual Variability in Patients Under Pharmacological Treatments. *Current Drug Metabolism*, v. 11, 276-282. 2010.
HERSBERGER, M; et al. Rapid Detection of the CYP2D6*3, CYP2D6*4, and CYP2D6*6 Alleles by Tetra-Primer PCR and of the CYP2D6*5 Allele by Multiplex. *Rev. Clinical Chemistry*, v.46. 2000.
HICKS J.K., et al. Clinical Pharmacogenetics Implementation consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants. *Clinical Pharmacology and Therapeutics*, 2013.
HICKS J.K., et al. Clinical Pharmacogenetics Implementation consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants. *Clinical Pharmacology and Therapeutics*, 2013.
MUNANGA, Kabengele. Diversity, ethnicity, identity and citizenship. *Rev. Soc. USP*, v.6, n.8, 2007.
SISTONEN, J; et. al. CYP2D6 worldwide genetic variation shows frequency of altered activity variants and no continental structure. *Pharmacogenet Genomics*, v. 17, n. 2. 2007.
ZHOU, S.F. Polymorphism os Human Cytochrome P450 2D6 and its Clinical Significance. *Clin Pharmacokinet*, v. 48, n. 11. 2009.
